Skip to content

A single-centre, placebo-controlled, crossover study in healthy medical registrars to enable validation of the mini-neurocart with the laparoscopy box trainer

A single-centre, placebo-controlled, crossover study in healthy medical registrars to enable validation of the mini-neurocart with the laparoscopy box trainer - FTOP - validation MiniNC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38449
Enrollment
18
Registered
2013-11-20
Start date
2013-12-03
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Validatiestudie fitheidstest (psychomotor/CNS) voor medisch specialisten Fit to perform test

Interventions

Ethanol intravenous administration: Prior to a study occasion, the study statistician will prepare individual computer spreadsheets, according to a randomized schedule. For alcohol occasions, this
a spread sheet-based paradigm using BrEC guided adjustments of infusion rates will be used to maintain stable levels. 2. Clamping procedure will be modified to achieve a stable pseudo-steady state l
a spread sheet-based paradigm using BrEC guided adjustments of infusion rates will be used to maintain stable levels. Placebo intravenous administration: For placebo occasions, the spreadsheet cont

Sponsors

Centre for Human Drug Research
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Subjects are healthy specialist registrars in one of the following specialist fields of medicine; a. Surgery; b. Urology; c. Gynaecology. 2. Subjects have completed one/both of the following courses: advanced Suturing Course (ASC) or OCEH; 3. Written informed consent; 4. Willing to comply with the study restrictions.

Exclusion criteria

Exclusion criteria: 1. Comorbidity or used pharmacological agents affected by alcohol; 2. Subject did not abstain from alcohol usage during the period from 48 hours prior to testing until discharge from the CRU; 3. Subject is is not able to refrain from use of (methyl) xanthines (e.g. coffee, tea, cola, chocolate) from 48 hours prior to dosing until discharge from the CRU; 4. Subject has used other stimulant or depressant medicines or substances during the 24 hours prior to testing; 5. Subject is unable to refrain from the use of concomitant medication which, in the opinion of the investigator, interferes with their ability to participate in the study, from 7 days prior to dosing until discharge from the CRU; 6. Subject does not have veins suitable for cannula placement; 7. Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject.

Design outcomes

Primary

MeasureTime frame
1. Subjective outcome parameters: VAS Bond and Lader a. Alertness b. Mood c. Personal stress level d. Self assessment of ability to perform 2. Objective parameters: a. Vigilance/Alertness (Adaptive tracking) b. Visuomotor coordination (Adaptive tracking) c. Stop signal response inhibition (Stop Signal Test) d. General CNS-activity (Visual analogue scores) e. Laparoscopic motion and force tracking (Force Motion Surgical Trainer)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)